A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205

Healthy Subjects Clinical Trial

Official title:

A Phase 1 Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of ASP2205

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02314793
• Other study ID #: 2205-CL-0001
• Secondary ID: 2014-003059-71
• Status: Terminated
• Phase: Phase 1
• First received: December 8, 2014
• Last updated: June 17, 2016
• Start date: November 2014
• Est. completion date: October 2015

Study information

• Verified date: June 2016
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of single ascending oral doses of ASP2205 in healthy young male and female subjects. This study will also evaluate the safety and tolerability of multiple ascending oral doses of ASP2205 in healthy young and elderly female subjects.

Description:

Part 1 is a single ascending dose investigator-blinded study in healthy young male and female subjects. Six doses of ASP2205 or matching placebo will be given to separate cohorts consisting of 8 subjects each, with 6 subjects receiving ASP2205 and 2 subjects receiving matching placebo. ASP2205 or matching placebo will be given as a single oral dose under fasted conditions.

The effect of a high-calorie high-fat meal (breakfast) on the safety, tolerability and pharmacokinetics of a single oral dose of ASP2205 will be evaluated in a separate cohort of 8 subjects in an open-label manner.

Part 2 is a multiple ascending dose subject- and investigator-blinded study comprising 3 cohorts with each 12 healthy young (aged 25 to 55 years) female subjects and 1 cohort with 12 healthy elderly (aged 65 years or older) female subjects who will receive ASP2205 or matching placebo. Nine subjects in each cohort will be treated with ASP2205 and 3 subjects will be treated with matching placebo (ratio 3:1).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 93
• Est. completion date: October 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 25 Years and older

Eligibility

Inclusion Criteria:

• Subject is a healthy young male or female subject aged 25 to 55 years, inclusive, at screening (part 1 and 2) or healthy elderly female subject aged = 65 years, inclusive, at screening (part 2 only).

• Subject has a body mass index (BMI) range of 18.5 - 30.0 kg/m2, inclusive. The subject weighs at least 50 kg (at screening).

• Subject agrees not to participate in another interventional study while participating in the present study, defined as signing the informed consent form until completion of the last study visit.

Exclusion Criteria:

• Female subject who has been pregnant within 6 months prior to screening assessment or breastfeeding within 3 months prior to screening.

• Subject has a known or suspected hypersensitivity to ASP2205 or any components of the formulations used.

• Subject has any of the liver function tests (LTs; aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase (ALP), gamma glutamyl transferase, total bilirubin [TBL]) above the upper limit of normal (ULN). In such a case, the assessment may be repeated once (admission to the clinical unit).

• Subject has at screening any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies).

• Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic (including surgical procedures to treat pelvic trauma), pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy.

• Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (noncutaneous) infection within 1 week prior to admission to the clinical unit.

• Subject has a relevant history of attempted suicide or suicidal behavior. Any recent suicidal ideation within the last 6 months or who are at significant risk to commit suicide.

• Subject has any clinically significant abnormality.

• Subject has a mean pulse < 40 or > 90 bpm; mean systolic blood pressure (SBP) > 140 mmHg; mean DBP > 90 mmHg (elderly subjects: mean SBP > 160 mmHg; mean DBP > 100 mmHg) (vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically) prior to the admission to the clinical unit (triplicates taken at screening and on admission to the clinical unit). If the mean blood pressure exceeds the limits above, 1 additional triplicate can be taken.

• Subject has a mean corrected QT interval using Fridericia's formula (QTcF) > 430 ms (for male subjects) and > 450 ms (for female subjects) at admission to the clinical unit. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken.

• Subject uses any prescribed or nonprescribed drugs (including vitamins, natural and herbal remedies, e.g., St. John's Wort) in the 2 weeks prior to study drug administration, except for occasional use of paracetamol (up to 2 g/day) and except for use of contraceptives or hormone replacement therapy.

• Subject has a history of smoking within 6 months prior to admission to the clinical unit.

• Subject has a history of drinking > 21 units of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) (> 14 units of alcohol for female subjects) within 3 months prior to admission to the clinical unit.

• Subject uses grapefruit juice (more than 3 × 200 mL) or products containing grapefruit and/or Seville oranges (more than 3 times) in the week prior to admission to the clinical unit until ESV, as reported by the subject.

• Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit.

• Subject regularly uses any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to admission to the clinical unit.

• Subject had significant blood loss, donated 1 unit (500 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to admission to the clinical unit.

• Subject has a positive serology test for hepatitis B surface antigen (HBsAg), hepatitis A virus antibodies (immunoglobulin M) (anti-HAV [IgM]), hepatitis C virus antibodies (anti-HCV) or antibodies to human immunodeficiency virus type 1 (HIV-1) and/or type 2 (HIV-2) at screening.

• Subject has been treated with any investigational drugs within 90 days or 5 terminal half-lives, whichever is longer, prior to drug administration.

• Subject is unable to communicate, read and understand English, or has any other condition which makes the subject unsuitable for study participation.

• Subject is an employee of the Astellas Group or Clinical Research Organization involved in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Healthy Subjects
• Pharmacokinetics of ASP2205

Intervention

Drug:
• ASP2205
oral
• Placebo
oral

Locations

Country	Name	City	State
United Kingdom	Site GB44001	Harrow

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Europe B.V.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1 and Part 2: Safety assessed by nature, frequency and severity of adverse events		up to 29 days	No
Primary	Part 1 and Part 2: Safety assessed by vital signs	Vital signs include blood pressure, pulse rate, body temperature	up to 29 days	No
Primary	Part 1 and Part 2: Safety assessed by orthostatic challenge test		up to 29 days	No
Primary	Part 1 and Part 2: Assessment of clinical laboratory tests	Clinical laboratory tests include hematology, biochemistry and urinalysis	up to 29 days	No
Primary	Part 1 and Part 2: Safety assessed by routine 12 lead electrocardiogram (ECG)		up to 29 days	No
Primary	Part 1 and Part 2: Safety assessed by continuous cardiac monitoring (Holter ECG)		up to 29 days	No
Primary	Part 1: Safety assessed by real-time cardiac monitoring (ECG telemetry)		up to 16 days	No
Secondary	Part 1 and Part 2: Safety laboratory test: prolactin		up to 29 days	No
Secondary	Part 1 and Part 2: Safety laboratory test: cortisol		up to 29 days	No
Secondary	Part 1 and Part 2: Safety laboratory test: bicarbonate (HCO3)		up to 29 days	No
Secondary	Part 1 and Part 2: Safety assessed by chemistry profile	Chemistry profile includes total cholesterol, high-density lipoprotein (HDL) / low-density lipoprotein (LDL), triglycerides	up to 29 days	No
Secondary	Part 1 and Part 2: Safety laboratory test: fasting blood glucose		up to 29 days	No
Secondary	Part 1 and Part 2: Safety laboratory test: creatinine urine		up to 29 days	No
Secondary	Part 1: Central nervous system (CNS) safety monitoring: Bond & Lader visual analogue scale (VAS)		up to 4 days	No
Secondary	Part 1: CNS safety monitoring: Drug effects questionnaire (DEQ) VAS	PhenX toolkit version	up to 4 days	No
Secondary	Part 1: Pharmacokinetics profile of ASP2205 in plasma: AUCinf, AUCinf (% extrapolated), AUClast, AUC24, CL/F, Cmax, terminal elimination rate constant, MRT, tlag, tmax, t1/2, Vz/F	Area under the concentration-time curve (AUC) from the time of dosing extrapolated to time infinity (AUCinf), percentage of AUCinf due to extrapolation from tlast to time infinity (AUCinf %extrapolated), AUC from the time of dosing to the last measurable concentration (AUClast), AUC from the time of dosing to 24 hours (AUC24), apparent total systemic clearance after single or multiple extravascular dosing (CL/F), maximum concentration (Cmax), mean residence time (MRT), time prior to the time corresponding to the first measurable (nonzero) concentration (tlag), time to maximum concentration (tmax), terminal elimination half-life (t1/2), apparent volume of distribution during the terminal elimination phase after single or multiple extravascular dosing (Vz/F)	Day 1	No
Secondary	Part 1: Pharmacokinetics profile of ASP2205 in urine: Aeinf, Aeinf%, Aelast, Aelast%, CLR	Cumulative amount of drug excreted into urine from time of dosing extrapolated to time infinity (Aeinf), percentage of drug dose excreted into urine from time of dosing extrapolated to time infinity (Aeinf%), cumulative amount of drug excreted into urine from time of dosing up to the collection time of the last measurable concentration (Aelast), percentage of drug dose excreted into urine from time of dosing up to the collection time of the last measurable concentration (Aelast%), renal clearance (CLR)	Day 1	No
Secondary	Part 2: Safety laboratory test: di-docosahexaenoyl-bis(monoacylglycerol) phosphate (di-22:6-BMP) in serum and urine		up to 29 days	No
Secondary	Part 2: CNS safety monitoring: CogState's neurocognition test battery (short version)		up to 14 days	No
Secondary	Part 2: CNS safety monitoring: Bond & Lader VAS		up to 17 days	No
Secondary	Part 2: CNS safety monitoring: DEQ VAS	PhenX toolkit version	Time Frame : up to 13 days	No
Secondary	Part 2: CNS safety monitoring: Addiction Research Center Inventory (49-item short form) (ARCI-49)		up to 13 days	No
Secondary	Part 2: CNS safety monitoring: Physician Withdrawal Checklist		up to 29 days	No
Secondary	Part 2: CNS safety monitoring: Columbia - Suicide Severity Rate Scale (C-SSRS)		up to 29 days	No
Secondary	Part 2: Appetite visual analogue scale (AVAS)		up to 15 days	No
Secondary	Part 2: Nausea VAS	From the McGill Nausea questionnaire	up to 15 days	No
Secondary	Part 2: Body weight		up to 29 days	No
Secondary	Part 2: Total daily urine production (24-hour volume)		up to 15 days	No
Secondary	Part 2: Total daily urine osmolality (24 hour pooled sample from each void)		up to 15 days	No
Secondary	Part 2: Total daily fluid intake		up to 15 days	No
Secondary	Part 2: Pharmacokinetic profile of ASP2205 in plasma: AUC24, Cmax, tlag, tmax		Day 1	No
Secondary	Part 2: Pharmacokinetic parameter: Ctrough		Day 1 immediately prior to dosing (morning Ctrough and, only in case of twice daily dosing, evening C trough): days 2, 4, 6, 8, 10, 12	No
Secondary	Part 2: Pharmacokinetic profile of ASP2205 in plasma: AUCtau, Cmax, tmax		Days 12, 13 (in case of twice daily dosing)	No
Secondary	Part 2: Pharmacokinetic profile of ASP2205 in plasma: AUCtau, CL/F, Cmax, terminal elimination rate constant, MRT, peak trough ratio (PTR), accumulation ratio calculated using the area under the concentration -time curve [Rac(AUC)], tmax, t1/2, VzF		Day 14	No
Secondary	Part 2: Pharmacokinetic profile of ASP2205 in urine: Aetau, Aetau%, CLR		Day 14	No